KRAS and neoplasm: Adoptive cell transfer using tumor-infiltrating lymphocytes (TILs) or T cell receptor–engineered (TCR-engineered) T cells targeting a common oncogenic KRAS mutation can induce durable tumor regression in patients with metastatic epithelial cancer (1, 2), providing a promising strategy for treating solid cancers with KRAS mutations.